Soleno Therapeutics (NASDAQ:SLNO) Price Target Lowered to $100.00 at HC Wainwright

Soleno Therapeutics (NASDAQ:SLNO) had its price target reduced by HC Wainwright from $120.00 to $100.00 in a research report report published on Wednesday morning, MarketBeat reports. They currently have a buy rating on the stock.

Several other equities research analysts have also weighed in on the company. Wall Street Zen lowered Soleno Therapeutics from a “buy” rating to a “hold” rating in a report on Saturday, February 28th. Wells Fargo & Company cut their target price on shares of Soleno Therapeutics from $114.00 to $110.00 and set an “overweight” rating for the company in a research report on Friday, February 27th. Weiss Ratings reissued a “sell (d-)” rating on shares of Soleno Therapeutics in a research report on Thursday, January 22nd. Wolfe Research set a $60.00 price target on shares of Soleno Therapeutics in a research note on Monday, January 12th. Finally, TD Cowen reduced their price objective on shares of Soleno Therapeutics from $120.00 to $85.00 and set a “buy” rating for the company in a research note on Thursday, February 26th. One equities research analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $106.85.

Soleno Therapeutics Price Performance

SLNO opened at $38.13 on Wednesday. Soleno Therapeutics has a fifty-two week low of $32.63 and a fifty-two week high of $90.32. The firm has a 50-day moving average of $41.98 and a 200 day moving average of $52.52. The company has a debt-to-equity ratio of 0.11, a quick ratio of 5.55 and a current ratio of 5.80. The firm has a market cap of $1.97 billion, a P/E ratio of 165.79 and a beta of -3.16.

Soleno Therapeutics (NASDAQ:SLNO) last announced its quarterly earnings data on Wednesday, February 25th. The company reported $0.80 EPS for the quarter, topping the consensus estimate of $0.64 by $0.16. The company had revenue of $91.73 million during the quarter, compared to the consensus estimate of $88.55 million. On average, research analysts expect that Soleno Therapeutics will post -3.72 EPS for the current year.

Institutional Trading of Soleno Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of SLNO. Caitong International Asset Management Co. Ltd bought a new position in Soleno Therapeutics in the 4th quarter valued at $38,000. Seven Fleet Capital Management LP purchased a new position in shares of Soleno Therapeutics during the fourth quarter worth about $6,023,000. Virtu Financial LLC bought a new position in shares of Soleno Therapeutics in the fourth quarter worth approximately $1,059,000. Empowered Funds LLC bought a new position in shares of Soleno Therapeutics in the fourth quarter worth approximately $69,000. Finally, KVP Capital Advisors LP purchased a new stake in Soleno Therapeutics in the fourth quarter valued at approximately $2,764,000. Institutional investors own 97.42% of the company’s stock.

About Soleno Therapeutics

Soleno Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development and commercialization of therapies for rare and orphan diseases. Headquartered in Redwood City, California, Soleno leverages a precision medicine approach to identify and advance small‐molecule treatments that address underlying genetic and metabolic dysfunctions. The company’s scientific strategy centers on repurposing and reformulating existing compounds to maximize therapeutic benefit in underserved patient populations.

The company’s lead candidate, diazoxide choline controlled release (DCCR), is being investigated for the treatment of Prader-Willi syndrome (PWS), a complex neurodevelopmental disorder characterized by insatiable appetite, hormonal imbalances and behavioral challenges.